Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four distinct pharmaceutical medications: lacosamide, lamotrigine, methylprednisolone, and perampanel, each with their own properties and uses. ### Lacosamide (Vimpat) Lacosamide is an anticonvulsant medication with a unique mode of action. It's used to treat partial-onset seizures (focal seizures) and primary generalized tonic-clonic seizures. It can be taken alone or in combination with other antiepileptic drugs. Lacosamide is available as both brand-name (Vimpat) and generic versions and is classified as a schedule V controlled substance. ### Lamotrigine (Lamictal) Lamotrigine is a phenyltriazine antiepileptic drug used to treat certain types of epilepsy and bipolar I disorder. It's available in immediate-release and extended-release formulations. The immediate-release version can also be used for bipolar disorder. Lamotrigine works by stabilizing neuronal membranes and inhibiting the release of excitatory neurotransmitters. ### Methylprednisolone (Medrol) Methylprednisolone is a corticosteroid similar to a natural hormone produced by the adrenal glands. It's used to treat various conditions by reducing inflammation and modifying the body's immune response. These conditions include endocrine disorders, rheumatic disorders, collagen diseases, skin diseases, severe allergies, eye problems, gastrointestinal problems, respiratory problems, blood disorders, neoplastic diseases, multiple sclerosis flare-ups, and certain infections. ### Perampanel Perampanel is an antiepileptic medication. Specific information about its mechanism was not provided in the search results. ### Drug Interactions The search results indicate some important interactions between these medications: - Lacosamide and lamotrigine together can increase the risk of an irregular heart rhythm that may be serious. - A study found that the combination of lacosamide with lamotrigine showed synergistic anticonvulsant effects in a 6-Hz-induced seizure model in mice, without enhanced adverse effects on motor coordination. - However, another study found that the three-drug combination of lacosamide, lamotrigine, and valproate showed sub-additive (antagonistic) interaction in a maximal electroshock-induced seizures model in mice. The specific four-drug combination of lacosamide, lamotrigine, methylprednisolone, and perampanel was not directly addressed in the search results, and the interactions among all four drugs together would need further investigation. Given the potential for serious interactions between just two of these medications (lacosamide and lamotrigine), the four-drug combination would require careful medical supervision and monitoring for adverse effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lacosamide + lamotrigine + methylprednisolone + perampanel.